This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Subscribe To Our Newsletter & Stay Updated
